Based in the biotech hub of San Diego, our in-house expertise of our people and global collaborations with academic and industry partners allow us to discover novel therapeutic targets and develop innovative therapeutics.
Neuropore Therapies, Inc. has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.
Report in Brain, describes findings supporting the hypothesis that NPTTM100-18A reduces alpha-synuclein toxicity through a novel mechanism that involves displacing pathological alpha-synuclein from the membrane.
Learn about Neuropore’s two part development strategy targeting misfolded proteins -- the key pathological culprit(s) underlying neurodegenerative disorders.
